Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.

"The article, entitled "Adenosine A3 Receptor Agonists as Multisystemic Disease Modifiers: From Molecular Signaling to Clinical Translation" was published in the peer-reviewed Biomolecules Journal (link). The publication reviews findings from Can-Fite work and numerous independent academic and clinical research groups worldwide demonstrating that activation of the A3 adenosine receptor (A3AR) modulates key pathological pathways involved in:

The review details evidence supporting A3AR agonist activity in:

  • Solid tumors, including hepatocellular carcinoma and pancreatic cancer
  • Metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis
  • Autoimmune and inflammatory diseases
  • Osteoarthritis and musculoskeletal disorders
  • Neurodegenerative diseases, including Alzheimer's disease and vascular dementia
  • Obesity and metabolic disorders
  • Rare genetic diseases, including Lowe syndrome